AMICUS THERAPEUTICS, INC. — Director's Dealing 2019

Feb 27, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2019-02-25

Reporting Person: Barth Jay (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-25	Common Stock	M	26270	$2.29	Acquired	156037	Direct
2019-02-25	Common Stock	S	26270	$12.5162	Disposed	129767	Direct
2019-02-25	Common Stock	M	43730	$2.94	Acquired	173497	Direct
2019-02-25	Common Stock	S	43730	$12.5162	Disposed	129767	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-25	Stock Options (right to buy)	$2.29	M	26270	Disposed	2024-03-03	Common Stock (26270)	Direct
2019-02-25	Stock Options (right to buy)	$2.94	M	43730	Disposed	2024-06-26	Common Stock (43730)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	31	Indirect

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2018.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.50 to $12.58. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of the options were fully vested and exercisable as of February 25, 2019.